The binding of programmed death 1 (PD-1) to its ligands PD-L1 and PD-L2 on antigen-presenting cells turns off autoreactive T cells and induces peripheral tolerance. Aberrant PD-1/PD-L signalling could result in a breakdown of peripheral tolerance and lead to autoimmune diseases. In this study, we detected PD-1 and PD-L expression on T cells and dendritic cells (DCs) in immune thrombocytopaenia (ITP) patients with active disease by flow cytometry. The effects of PD-L1-Fc fusion protein (PD-L1-Fc) on T cells and on secretion of interferon-γ (IFN-γ) and interleukin-2 (IL-2) were detected by flow cytometry and enzyme-linked immunosorbent assay, respectively. Compared with healthy controls, PD-1 expression was significantly increased in CD4+ T cells and CD8+ T cells from patients with active ITP. However, PD-L1 expression on monocyte-derived DCs was lower in patients with active ITP than in healthy controls. In vitro assays revealed that PD-L1-Fc increased T cell apoptosis, inhibited activation and proliferation of CD4+ T cells and CD8+ T cells and decreased IFN-γ and IL-2 secretion in patients with active ITP. These results suggest that the aberrant PD-1/PD-L negative co-stimulatory pathway may play a role in ITP. Enhancing PD-1/PD-L signalling might be a promising therapeutic approach for ITP patients by enhancing T cell apoptosis, inhibiting T cell activation and proliferation and reducing secretion of inflammatory factors. M.N. and X.-x.L. performed research, analysed data and wrote the manuscript; Y.L., D.-d.Y., Q.L. and Y.H. performed research; Y.-n.M. and Q.F. performed research and analysed data; G.-s.L. and J.-z.S. analysed data; Y.S. contributed vital new reagents, designed the study and wrote the manuscript; M.H. revised the manuscript; and all authors read and edited the manuscript. Part of this study was orally presented at the 9th Congress of the Asian-Pacific Society on Thrombosis and Hemostasis, Taipei, Taiwan, China, October 6–9, 2016, and part of this study was presented as a poster at the 60th American Society of Hematology Annual Meeting, San Diego, California, United States, December 1–4, 2018. * M.N. and Y.L. contributed equally to this study.